Nowadays, fixed drug combinations are very important part of pharmacotherapy in essential arterial hypertension. The ameliorated activity of RAAS system (ACE inhibitors or sartans) along with calcium-ion channel inhibitor results in additive decrease of blood pressure with concomitant beneficial safety profile.
Both telmisartan and amlodipine possess very favorable pharmacological properties, what is reflected in results of performed clinical trials, in which they were used as combinations.